Skip to main content

PDL BioPharma Value Stock - Dividend - Research Selection

PDL BioPharma

ISIN: US69329Y1047, WKN: A0H1J1

Market price date: 25.01.2021
Market price: 2,47 USD




PDL BioPharma Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-03-2020
Cash flow
Net operating cash flow -32.443.000
Capital Expenditures -2.463.000
Free cash flow -34.906.000
Balance sheet
Total Equity 593.200.000
Liabilities & Shareholders equity 716.119.000
Income statement
Net income -70.411.000
Eps (diluted) -0,590
Diluted shares outstanding 118.631.000
Net sales/revenue 433.000

Fundamental ratios calculated on: 25-01-2021

Ratios
Key figures 25-01-2021
Cash flow
P/C -9,03
   
P/FC -8,40
Balance sheet
ROI-9,83
ROE82,84
Income statement
P/E-4,19
Div. Yield0,00%
P/B0,49
P/S676,72


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolPDLI
Market Capitalization293.018.560,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split2001-10-10,2.0000/1.0000; 2000-08-23,2.0000/1.0000
Internetwww.pdl.com


Description of the company

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.pdl.com